GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-02-20|

Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease

by GeneOnline
Share To
  • Co-research and co-development of novel microbiome therapeutics
  • Discovery of new candidates to meet high unmet medical needs in Parkinson’s disease

SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ — LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology with precision targets, announced a multi-year strategic R&D collaboration with Celltrion to identify novel microbiome therapy for Parkinson’s disease.

Under the agreement, Celltrion and LISCure intend to develop oral live biotherapeutic products (LBPs) for Parkinson’s disease. LISCure will receive research funding and is eligible to receive additional payments as the project progresses. LISCure will lead discovery of novel candidates and Celltrion will be responsible for further clinical and regulatory development.

Parkinson’s disease is known to occur due to a low level of dopamine and abnormal aggregation of α-synuclein associated with gut dysbiosis, suggesting that microbiome-based therapies are potential therapeutic strategies for novel treatments of Parkinson’s disease.

LISCure advances brain-target bacterial exosome technology for neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease based on its platform technology. Celltrion intends to leverage the collaboration to expand its business strategy of microbiome therapy and strengthen neurodegenerative pipeline. 

The global market size of Parkinson’s disease treatment was valued at USD 3.5 billion in 2019 and is anticipated to reach USD 11.5 billion in 2029 (CAGR=12.6%). The US Parkinson’s disease market size was USD 1.8 billion in 2019 (market share = 51.5%)[1].

[1] REFERENCES : 2021 GlobalData

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top